Epoetin beta
From Wikipedia, the free encyclopedia
|
Epoetin beta
|
|
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Epoetin beta (rINN) (pronounced /ɛˈpoʊɨtɨn/) is a synthetic, recombinant[1] form of erythropoietin. It stimulates erythropoiesis (increases red blood cell levels) and is used to treat anemia, commonly associated with chronic renal failure and cancer chemotherapy.
Epoetin is marketed under the trade names NeoRecormon.[2] It is only sold in Europe.
[edit] References
- ^ Dunn CJ, Markham A (1996). "Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure". Drugs 51 (2): 299–318. PMID 8808169.
- ^ Amgen - Products. URL: http://www.amgen.com/patients/prca.html. Accessed on: October 21, 2007.
